Comparing two ways of monitoring pancreatic cysts over time
Compares checking pancreatic cysts more often with less often, and tests biomarkers.
Plain-language title generated from the registry record
Registry title: Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Key facts
- Where
- Hamilton, Kingston, New Westminster, and Toronto, CanadaSee the 4 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 50 to 75 who have a pancreatic cyst of 1 cm (0.4 in) or larger found on a recent scan. It compares more frequent and less frequent monitoring.
- Age
- 50 to 75 years
- Sex
- All sexes can join.
- Disease stage
- One or more pancreatic cysts of 1 cm (0.4 in) or larger, seen on a CT, MRI or EUS within the 6 months before enrolment.
- Earlier treatment
- No history of pancreatic surgery (resection). Not in cyst surveillance for more than 1 year.
Main reasons for not taking part
- Acute pancreatitis or a history of chronic pancreatitis
- Any earlier diagnosis of pancreatic cancer
- A first-degree relative with pancreatic adenocarcinoma
- Cyst features that need surgery right away
- Known pregnancy
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 75 years old?
Source: NCT04239573, who can take part
Where in Canada
- Juravinski Cancer Centre at Hamilton Health SciencesHamilton, CanadaNo longer taking part
- Kingston Health Sciences CentreKingston, CanadaNo longer taking part
- Royal Columbian HospitalNew Westminster, CanadaNo longer taking part
- Odette Cancer Centre, Sunnybrook Health Sciences CentreToronto, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- ECOG-ACRIN Cancer Research Group
- Trial code
- NCT04239573
- Record updated
- 4 September 2026
- Original description
The purpose of this study is to compare two approaches for monitoring pancreatic cysts as well as to identify associated biomarkers. The study doctors want to compare more frequent monitoring versus less frequent monitoring as well as identify biomarkers which may improve risk detection of transformation to pancreatic cancer. The study doctors want to learn which monitoring method and which biomarkers lead to better outcomes for patients.Read full original descriptionShow less
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
The purpose of this study is to compare two approaches for monitoring pancreatic cysts as well as to identify associated biomarkers. The study doctors want to compare more frequent monitoring versus less frequent monitoring as well as identify biomarkers which may improve risk detection of transformation to pancreatic cancer. The study doctors want to learn which monitoring method and which biomarkers lead to better outcomes for patients.
Inclusion: Patient must be ≥ 50 years and ≤ 75 years of age; Patient must not have acute pancreatitis or a history of chronic pancreatitis; Patient must have received a CT, MRI, or EUS within 6 months prior to enrollment that revealed one or more ≥ 1 cm pancreatic cyst(s); Patients of childbearing potential must not be known to be pregnant; Patient must not have a prior diagnosis of pancreatic malignancy of any type; Patient must not have a history of pancreatic resection; Patients with only pancreatic lesions without malignant risk (pancreatic pseudocyst or classic serous cystic lesion) are not eligible; Patient must not have a family history of pancreatic adenocarcinoma in one or more first-degree relatives (biological parents, full siblings or children); Patient must not have pancreatic cyst morphology that would prompt immediate surgical consideration (enhancing mural nodule, solid component in cyst, pancreatic duct ≥ 10mm, cyst causing obstructive jaundice); Patient must not have a comorbid illness that precludes EUS or pancreatic cyst resection; Patient must not be in any form of pancreatic cyst surveillance for > 1 year, defined as organized, periodic up-to-date imaging directed towards the pancreatic cyst of interest; PRIOR TO ADDENDUM #5 08/13/2024: Patient must be ≥ 50 years and ≤ 75 years of age; PRIOR TO ADDENDUM #5 08/13/2024: Patient must not have acute pancreatitis or a history of chronic pancreatitis; PRIOR TO ADDENDUM #5 08/13/2024: Patient must have received a CT, MRI, or EUS within 6 months prior to randomization that revealed one or more ≥ 1 cm pancreatic cyst (s); PRIOR TO ADDENDUM #5 08/13/2024: Patients of childbearing potential must not be known to be pregnant; PRIOR TO ADDENDUM #5 08/13/2024: Patient must not have a prior diagnosis of pancreatic malignancy of any type; PRIOR TO ADDENDUM #5 08/13/2024: Patient must not have a history of pancreatic resection; PRIOR TO ADDENDUM #5 08/13/2024: Patients with only pancreatic lesions without malignant risk (pancreatic pseudocyst or classic serous cystic lesion) are not eligible; PRIOR TO ADDENDUM #5 08/13/2024: Patient must not have a family history of pancreatic adenocarcinoma in one or more first-degree relatives (biological parents, full siblings or children); PRIOR TO ADDENDUM #5 08/13/2024: Patient must not have pancreatic cyst morphology that would prompt immediate surgical consideration (enhancing mural nodule, solid component in cyst, pancreatic duct ≥10mm, cyst causing obstructive jaundice); PRIOR TO ADDENDUM #5 08/13/2024: Patient must not have a comorbid illness that precludes EUS or pancreatic cyst resection.